Anti-Human ALK-1 Reference Antibody (Ascrinvacumab, RUO)

Description: Ascrinvacumab (BS10451) is a research-grade recombinant antibody targeting Serine/threonine-protein kinase receptor R3. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG2-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Serine/threonine-proteinkinasereceptorR3,ACVRL1,Activinreceptor-likekinase1,ALK-1,ACVRLK1,ALK1,SKR3,TGF-BsuperfamilyreceptortypeI,TSR-I
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: PF-03446962,CAS:1463459-96-2
Background: Activin receptor type-1-like (ACVRL1/ALK-1) is a ~56 kDa protein. Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well.
Note: For research use only. Not suitable for clinical or therapeutic use.